Timing of Antiretroviral Therapy for HIV-1 Infection and TuberculosisDiane V. Havlir, Ian Sanne, Michelle A. Kendall et al.|New England Journal of Medicine|2011Cited by 541
Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV InfectionÁlvaro H. Borges, Ronald T. Mitsuyasu, Jacqueline Neuhaus et al.|Clinical Infectious Diseases|2016Cited by 93
Translocated microbiome composition determines immunological outcome in treated HIV infectionKrystelle Nganou‐Makamdop, Daniel C. Douek, Torfi Hoskuldsson et al.|Cell|2021Cited by 81
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy studyBeatriz Grinsztejn, Michael D. Hughes, Justin Ritz et al.|The Lancet HIV|2019Cited by 39
Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trialAnchalee Avihingsanon, Michael D. Hughes, Robert A. Salata et al.|Journal of the International AIDS Society|2022Cited by 13